Inventor · disambiguated record
Jackson Eby
Also filed as: EBY JACKSON
4 granted patents·20 pending applications·4 citations·filing 2015–2025
66Inventor score
Files withRECODE THERAPEUTICS INC19ELICIO THERAPEUTICS INC3VEDANTRA PHANNACEUTICALS INC1VEDANTRA PHARMACEUTICALS INC1
Top patents by PatentIndex Score
24 records- 0190US12121610B2Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2023·Granted Oct 22, 2024·3 cites·32 claims
- 0282US2024374513A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0382US2024374514A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0482US2024390271A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0582US2024374512A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0682US2024390272A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0782US2024374511A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0880US12257318B2Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Granted Mar 25, 2025·0 cites·30 claims
- 0979US2025276091A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1079US2023338411A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1179US2024299310A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1279US2024277850A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1379US2024261432A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1478US2024245619A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1575US2024207178A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1672US12370245B2ALK polypeptides and methods of use thereofELICIO THERAPEUTICS INC·Filed 2023·Granted Jul 29, 2025·0 cites·9 claims
- 1772US11623002B2ALK polypeptides and methods of use thereofELICIO THERAPEUTICS INC·Filed 2017·Granted Apr 11, 2023·1 cites·5 claims
- 1872US2025325644A1Alk polypeptides and methods of use thereofELICIO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1972US2024398983A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2068US2025019409A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2159US2024216515A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2257US2024197641A1Compositions and methods for targeted systemic delivery to cellsRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2330US2018000906A1Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereofVEDANTRA PHANNACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2429US2017246288A1Multilamellar lipid vesicle compositions and methods of useVEDANTRA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jackson Eby files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →